Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Cahill

Showing results (71-80 of 196) with videos related to

Pageof 20
Sort By:
Acta Neuropathologica Communications|November 28, 2023
Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytomaKensuke Tateishi, Yohei Miyake, Taishi Nakamura, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Journal of Neurosurgery|November 26, 2016
Targeted sequencing of SMO and AKT1 in anterior skull base meningiomasMatthew R Strickland, Corey M Gill, Naema Nayyar, et al.
Nature Communications|August 16, 2024
Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomasSyeda Maheen Batool, Ana K Escobedo, Tiffaney Hsia, et al.
Cancer Research|June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated CytotoxicityKensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Journal of Neuro-Oncology|October 21, 2024
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial designEthan A Wetzel, Amin I Nohman, Annie L Hsieh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-HydroxyglutarateOvidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 27, 2021
In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic ImagingBijaya Thapa, Azma Mareyam, Jason Stockmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmentDaniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Cancers|July 12, 2025
A Review of Emerging Immunotherapeutic Strategies for IDH-Mutant GliomaMasih Tazhibi, Eric P Grewal, Rishab Ramapriyan, et al.
Pageof 20

Showing results (71-80 of 196) with videos related to

Sort By:
Pageof 20
Acta Neuropathologica Communications|November 28, 2023
Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytomaKensuke Tateishi, Yohei Miyake, Taishi Nakamura, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Journal of Neurosurgery|November 26, 2016
Targeted sequencing of SMO and AKT1 in anterior skull base meningiomasMatthew R Strickland, Corey M Gill, Naema Nayyar, et al.
Nature Communications|August 16, 2024
Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomasSyeda Maheen Batool, Ana K Escobedo, Tiffaney Hsia, et al.
Cancer Research|June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated CytotoxicityKensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Journal of Neuro-Oncology|October 21, 2024
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial designEthan A Wetzel, Amin I Nohman, Annie L Hsieh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-HydroxyglutarateOvidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 27, 2021
In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic ImagingBijaya Thapa, Azma Mareyam, Jason Stockmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmentDaniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Cancers|July 12, 2025
A Review of Emerging Immunotherapeutic Strategies for IDH-Mutant GliomaMasih Tazhibi, Eric P Grewal, Rishab Ramapriyan, et al.
Pageof 20